Suchergebnisse - (Person:"Jimenez-Fonseca, Paula")

PubPharm (7)

1

The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Borbath, I. | Garcia-Carbonero, R. | Bikmukhametov, D. | +11

2

External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms : The GETNE-TRASGU Study

enthalten in: Neuroendocrinology | 2022

von Jimenez-Fonseca, P. | Carmona-Bayonas, A. | Lamarca, A. | +25

3

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog : The GETNE-TRASGU Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Carmona-Bayonas, A. | Jiménez-Fonseca, P. | Lamarca, �. | +26

4

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

enthalten in: Cancer treatment reviews | 2018

von Barriuso, J. | Custodio, A. | Afonso, R. | +9

5

Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context

enthalten in: Advances in therapy | 2018

von Wagner, M. | Samaha, D. | Cuervo, J. | +4

6

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors

enthalten in: Current oncology reports | 2017

von Carmona-Bayonas, A. | Jiménez-Fonseca, P. | Custodio, A. | +6

7

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis

enthalten in: BMC cancer | 2015

von Capdevila, J. | Sevilla, I. | Alonso, V. | +16

1
[1]